Analytical Data
-
Gene name
CD46
- Application
-
Alternative Names
CD46；MCP；MIC10；Membrane cofactor Protein
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P15529
-
Expression Region
35-328aa
-
AA Sequence
CEEPPTFEAMELIGKPKPYYEIGERVDYKCKKGYFYIPPLATHTICDRNHTWLPVSDDACYRETCPYIRDPLNGQAVPANGTYEFGYQMHFICNEGYYLIGEEILYCELKGSVAIWSGKPPICEKVLCTPPPKIKNGKHTFSEVEVFEYLDAVTYSCDPAPGPDPFSLIGESTIYCGDNSVWSRAAPECKVVKCRFPVVENGKQISGFGKKFYYKATVMFECDKGFYLDGSDTIVCDSNSTWDPPVPKCLKVLPPSSTKPPALSHSVSTSSTTKSPASSASGPRPTYKPPVSNY
-
Molecular Weight
61.6 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CD46, also known as membrane cofactor protein (MCP), is a pivotal regulator of the complement system and plays a crucial role in immune response modulation. This glycoprotein exists on the surface of various human cells and functions to protect host tissues from complement-mediated lysis by serving as a cofactor for the inactivation of complement component C3b and C4b. Due to its immunoregulatory properties, CD46 has garnered attention in various research fields, including autoimmunity, transplantation, and cancer. Its unique expression patterns in different tissues and cells make it an attractive target for therapeutic applications. Researchers are investigating the potential of CD46 recombinant proteins as novel immunotherapies capable of modulating immune responses, enhancing graft survival in transplantation, and targeting tumor cells. Production of CD46 as a recombinant protein allows for the detailed study of its structure-function relationships and the development of CD46-based biopharmaceuticals. Understanding the molecular mechanisms underlying CD46 interactions and functions could lead to innovative strategies in treating immune-related diseases and improving clinical outcomes in organ transplantation and cancer therapies. Thus, the exploration of CD46 recombinant proteins not only deepens our understanding of the complement system but also opens avenues for novel immunotherapeutic strategies.
